Exelixis
EXEL
#2208
Rank
$5.41 B
Marketcap
$16.79
Share price
-0.89%
Change (1 day)
-1.58%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/E ratio for Exelixis (EXEL)

P/E ratio as of November 2022 (TTM): 17.5

According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.4896. At the end of 2021 the company had a P/E ratio of 24.7.

P/E ratio history for Exelixis from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202124.7-54.46%
202054.2226.32%
201916.694.37%
20188.55-85.09%
201757.4-234.64%
2016-42.6511.81%
2015-6.96572.12%
2014-1.04-77.69%
2013-4.64

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
24.4 39.23%๐Ÿ‡บ๐Ÿ‡ธ USA
9.34-46.62%๐Ÿ‡บ๐Ÿ‡ธ USA
22.5 28.86%๐Ÿ‡บ๐Ÿ‡ธ USA
13.8-21.03%๐Ÿ‡ซ๐Ÿ‡ท France
18.0 2.83%๐Ÿ‡บ๐Ÿ‡ธ USA
25.4 44.95%๐Ÿ‡บ๐Ÿ‡ธ USA
4.27-75.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
-1.31-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-17.7-201.15%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.